| HTSAB | human thyroid-stimulating antibody |
|---|---|
| LATS | long-acting thyroid stimulator |
| LATS-P | long-acting thyroid stimulator-protector |
| MCT | manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp... |
| MTC | mass transfer coefficient; maximum tolerated concentration; maximum toxic concentration; medical tes... |
| HP-beta-CyD | 2-Hydroxypropyl-beta-cyclodextrin |
|---|---|
| HP-beta-CD | 2-hydroxy)propyl beta-cyclodextrin |
| 3 beta-HSD | 3 beta hydroxy steroid dehydrogenase |
| 3 beta-HSD | 3 beta-Hydroxysteroid dehydrogenase/isomerase |
| 3 beta-HSD | 3 beta-Hydroxysteroid dehydrogenasel delta 5-->4-isomerase |
| adrenergic receptors | Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents. Synonym: adrenoceptor, adrenoreceptors. (05 Mar 2000) |
|---|---|
| alpha-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles. (05 Mar 2000) |
| ANP clearance receptors | Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action. (05 Mar 2000) |
| ANP receptors | Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains. (05 Mar 2000) |
| B-cell antigen receptors | In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors. (05 Mar 2000) |
| mannose-6-phosphate receptors | Receptors in Golgi apparatus to which newly synthesised proteins that are destined to enter lysosomes bind. (05 Mar 2000) |
| receptors, adrenergic | Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction. (12 Dec 1998) |
| receptors, adrenergic, alpha | One of the two major pharmacological subdivisions of adrenergic receptors. The alpha-beta distinction was originally based on cellular effects of receptor activation but now relies on the relative affinities for certain synthetic ligands. Alpha-adrenergic receptors are further subdivided into several subclasses based on studies of endogenous and cloned receptors. (12 Dec 1998) |
| receptors, adrenergic, alpha-1 | A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-1 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist phenylephrine and the antagonist prazosin. They are widespread, with clinically important concentrations in the liver, the heart, vascular, intestinal, and genitourinary smooth muscle, and the central and peripheral nervous systems. (12 Dec 1998) |
| receptors, adrenergic, alpha-2 | A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-2 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist clonidine and the antagonist yohimbine. They are found on pancreatic beta cells, platelets, and vascular smooth muscle, as well as both pre- and postsynaptically in the central and peripheral nervous systems. (12 Dec 1998) |
| receptors, albumin | Cell surface proteins that bind albumin with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
| receptors, aldosterone | Cytoplasmic proteins that specifically bind aldosterone and mediate its cellular effects. The aldosterone-bound receptor acts in the nucleus to regulate the transcription of specific segments of DNA. (12 Dec 1998) |
| receptors, amino acid | Cell surface proteins that bind amino acids and trigger changes which influence the behaviour of cells. Glutamate receptors are the most common receptors for fast excitatory synaptic transmission in the vertebrate central nervous system, and gaba and glycine receptors are the most common receptors for fast inhibition. (12 Dec 1998) |
| receptors, ampa | Cell surface proteins that bind glutamate and directly gate ion channels in cell membranes. Ampa receptors were originally discriminated from other glutamate receptors by their affinity for the agonist ampa (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid). They are probably the most common mediators of fast excitatory synaptic transmission in the central nervous system. Several subtypes have been cloned, and for some types the traditional distinction from kainate receptors may not apply. (12 Dec 1998) |
| receptors, androgen | Proteins, generally found in the cytoplasm, that specifically bind androgens and mediate their cellular actions. The complex of the androgen and receptor migrates to the nucleus where it induces transcription of specific segments of DNA. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|